Close
Enter your
text here
Posts By :

Vivek g

A novel approach to identifying Market Potential across Geographies
 A novel approach to identifying Market Potential across Geographies 874 600 Vivek g
By:

Quantifying potential and opportunities across the geographic segments, beyond the traditional approaches. DataZymes enabled identifying clusters with maximum potential and enhance sales force messaging effectiveness Challenge The pharma client, being a medium sized company and working with limited sales force was looking at enhancing the approach to quantify potential and opportunities across the geographic segments,…

read more
CaseStudy_Marketing-Mix
Measuring the impact of Covid on OPIODS Marketing
 Measuring the impact of Covid on OPIODS Marketing 874 600 Vivek g
By:

Market Mix Modeling to understand the impact of Covid-19 for a Long Acting Opiod. Challenge As the Opioids market is booming worldwide, our client, one of the top pharmaceutical companies, wanted to achieve brand’s strategic objectives of becoming the #1 LAO (Long Acting Opioid) in the market. One of the key prospects for the company…

read more
Setting up an Effective Data Quality Platform for Pharma
 Setting up an Effective Data Quality Platform for Pharma 874 600 Vivek g
By:

DZLumen TM, a complete Data Quality Platform purpose built for Pharma has helped clients improve Data Quality. Is your Data Accurate? Most companies cannot answer this question with confidence since they do not have a framework and process to measure quality of data across the Data Continuum. While syndicated data is assumed to be clean,…

read more
Improving sales through understanding patient behavior
 Improving sales through understanding patient behavior 874 600 Vivek g
By:

Integrating traditional patient studies like persistency, compliance, and length of therapy to better understand the behavior in dropping off a drug. How DataZymes combined different studies like persistency, compliance and length of therapy, handling data leakage to give better picture of patients’ behavior in longitudinal. Challenge Only one third of the patients are said to…

read more
Blog BI Adoption
What drives low BI Adoption in Pharma companies and what can they do?
 What drives low BI Adoption in Pharma companies and what can they do? 874 600 Vivek g
By:

BI investments in global healthcare are expected to reach around 10 BN by 2025, but companies are still struggling with low adoption. In the past few years, pharmaceutical organizations have been investing heavily on enterprise level BI solutions and technologies, to improve efficiencies, save costs and generate incremental value for business. According to a report…

read more
Contact us